{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:32:00Z","timestamp":1792801920519,"version":"4.5.0"},"reference-count":117,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2015.00279","type":"journal-article","created":{"date-parts":[[2015,12,23]],"date-time":"2015-12-23T06:20:49Z","timestamp":1450851649000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["Bone Tumor Environment as a Potential Therapeutic Target in Ewing Sarcoma"],"prefix":"10.3389","volume":"5","author":[{"given":"Fran\u00e7oise","family":"Redini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Heymann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2015,12,23]]},"reference":[{"key":"B1","first-page":"17","article-title":"Diffuse endothelioma of bone","volume":"21","author":"Ewing","year":"1921","journal-title":"Proc N Y Pathol Soc"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2006.12.009","article-title":"The biology of Ewing sarcoma","volume":"254","author":"Riggi","year":"2007","journal-title":"Cancer Lett"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1038\/sj.bjc.6603774","article-title":"Cellular and humoral mechanisms of osteoclast formation in Ewing\u2019s sarcoma","volume":"96","author":"Lau","year":"2007","journal-title":"Br J Cancer"},{"key":"B4","first-page":"1067","article-title":"Overexpression of the pseudoautosomal gene MIC2 in Ewing\u2019s sarcoma and peripheral primitive neuroectodermal tumor","volume":"5","author":"Kovar","year":"1990","journal-title":"Oncogene"},{"issue":"23","key":"B5","first-page":"1101","article-title":"Chromosomal translocation (11; 22) in cell lines of Ewing\u2019s sarcoma","volume":"296","author":"Turc-Carel","year":"1983","journal-title":"C R Seances Acad Sci III"},{"issue":"6391","key":"B6","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/359162a0","article-title":"Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours","volume":"359","author":"Delattre","year":"1992","journal-title":"Nature"},{"issue":"40","key":"B7","doi-asserted-by":"publisher","first-page":"5747","DOI":"10.1038\/sj.onc.1204598","article-title":"Biology of EWS\/ETS fusions in Ewing\u2019s family tumors","volume":"20","author":"Arvand","year":"2001","journal-title":"Oncogene"},{"issue":"12","key":"B8","doi-asserted-by":"publisher","first-page":"5752","DOI":"10.1073\/pnas.90.12.5752","article-title":"Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation","volume":"90","author":"May","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"25","key":"B9","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1038\/sj.onc.1204437","article-title":"Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression","volume":"20","author":"Dauphinot","year":"2001","journal-title":"Oncogene"},{"issue":"4","key":"B10","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/00001622-199807000-00010","article-title":"Ewing\u2019s sarcoma and peripheral primitive neuroectodermal tumors after their genetic union","volume":"10","author":"Kovar","year":"1998","journal-title":"Curr Opin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1158\/1078-0432.CCR-09-2261","article-title":"Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing\u2019s sarcoma","volume":"16","author":"Erkizan","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3109\/08880018.2011.627582","article-title":"Ewing sarcoma: biology-based therapeutic perspectives","volume":"29","author":"Potratz","year":"2012","journal-title":"Pediatr Hematol Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1200\/JCO.2014.59.5256","article-title":"Ewing sarcoma: current management and future approaches through collaboration","volume":"27","author":"Gaspar","year":"2015","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1111\/j.1349-7006.2009.01177.x","article-title":"Cancer stem cells and their niche","volume":"100","author":"Iwasaki","year":"2009","journal-title":"Cancer Sci"},{"key":"B15","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2174\/138920109787847493","article-title":"Multiple myeloma bone marrow niche","volume":"10","author":"Basak","year":"2009","journal-title":"Curr Pharm Biotechnol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(00)49915-0","article-title":"The distribution of secondary growths in cancer of the breast","volume":"133","author":"Paget","year":"1889","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1172\/JCI28568","article-title":"The stem cell niches in bone","volume":"116","author":"Yin","year":"2006","journal-title":"J Clin Invest"},{"key":"B18","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1182\/blood-2009-05-224857","article-title":"Knockdown of N-cadherin suppresses the long-term engraftment of hematopoietic stem cells","volume":"116","author":"Hosokawa","year":"2010","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/B978-0-12-374895-9.00003-7","article-title":"Early bone metastasis-associated molecular and cellular events","volume-title":"Bone Cancer","author":"Cl\u00e9zardin","year":"2010"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/path.2727","article-title":"Current and emerging concepts in tumour metastasis","volume":"222","author":"Coghlin","year":"2010","journal-title":"J Pathol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1200\/JCO.2010.28.4257","article-title":"Tumor-host interactions: a far-reaching relationship","volume":"28","author":"Mc Allister","year":"2010","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1242\/jcs.116392","article-title":"The tumor microenvironment at a glance","volume":"125","author":"Balkwill","year":"2012","journal-title":"J Cell Sci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.1158\/0008-5472.CAN-13-0661","article-title":"Targeting the tumor microenvironment: from understanding pathways to effective clinical trials","volume":"73","author":"Fang","year":"2013","journal-title":"Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1158\/1541-7786.MCR-13-0535","article-title":"Insidious changes in stromal matrix fuel cancer progression","volume":"12","author":"Miles","year":"2014","journal-title":"Mol Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1158\/1078-0432.CCR-11-2186","article-title":"Cancer dormancy: a model of early dissemination and late cancer occurrence","volume":"18","author":"Paez","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cytogfr.2004.06.004","article-title":"The molecular triad OPG\/RANK\/RANKL: involvement in the orchestration of pathophysiological bone remodeling","volume":"15","author":"Theoleyre","year":"2004","journal-title":"Cytokine Growth Factor Rev"},{"key":"B27","first-page":"49","article-title":"RANKL\/RANK\/OPG: new therapeutic targets in bone tumours and associated osteolysis","volume":"1704","author":"Wittrant","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/932451","article-title":"The bone niche of chondrosarcoma: a sanctuary for the drug resistance, the tumour growth and also a source of new therapeutic targets","volume":"2011","author":"David","year":"2011","journal-title":"Sarcoma"},{"key":"B29","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"B30","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/bonekey.2015.57","article-title":"Bone marrow as a metastatic niche for disseminated tumor cells from solid tumors","volume":"4","author":"Shiozawa","year":"2015","journal-title":"Bonekey Rep"},{"key":"B31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ctrv.2014.12.001","article-title":"Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment","volume":"41","author":"Criscitiello","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"B32","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1615\/CritRevEukarGeneExpr.v10.i2.50","article-title":"Molecular mechanisms of tumor-bone interactions in osteolytic metastases","volume":"10","author":"Chirgwin","year":"2000","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.2174\/1381612033453640","article-title":"New insights into the molecular mechanisms of action of bisphosphonates","volume":"9","author":"Rogers","year":"2003","journal-title":"Curr Pharm Des"},{"issue":"Suppl 8","key":"B34","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1699::AID-CNCR23>3.0.CO;2-U","article-title":"Zoledronate","volume":"80","author":"Body","year":"1997","journal-title":"Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2165\/00003495-200161060-00010","article-title":"Zoledronic acid","volume":"61","author":"Cheer","year":"2001","journal-title":"Drugs"},{"key":"B36","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2165\/00002512-199915040-00004","article-title":"New bisphosphonates in the treatment of bone diseases","volume":"15","author":"Gatti","year":"1999","journal-title":"Drugs Aging"},{"key":"B37","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/(SICI)1097-0185(199712)249:4458::AID-AR53.0.CO;2-N","article-title":"Effects of short-term treatment with the bisphosphonate zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before, during, and after treatment","volume":"249","author":"Pataki","year":"1997","journal-title":"Anat Rec"},{"key":"B38","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.clinthera.2006.02.007","article-title":"Update of current therapeutic options for the treatment of postmenopausal osteoporosis","volume":"28","author":"Epstein","year":"2006","journal-title":"Clin Ther"},{"key":"B39","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.molmed.2004.05.007","article-title":"Bisphosphonates: new therapeutic agents for the treatment of bone tumors","volume":"10","author":"Heymann","year":"2004","journal-title":"Trends Mol Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/sj.bjc.6604382","article-title":"Risks and benefits of bisphosphonates","volume":"98","author":"Coleman","year":"2008","journal-title":"Br J Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1359\/jbmr.060118","article-title":"Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases","volume":"21","author":"Dunford","year":"2006","journal-title":"J Bone Miner Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1359\/jbmr.2000.15.8.1467","article-title":"Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298","volume":"15","author":"Coxon","year":"2000","journal-title":"J Bone Miner Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S8756-3282(01)00412-4","article-title":"Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro","volume":"28","author":"Benford","year":"2001","journal-title":"Bone"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/jbmr.5650101008","article-title":"Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo","volume":"10","author":"Hughes","year":"1995","journal-title":"J Bone Miner Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1006\/bbrc.2002.6510","article-title":"Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts","volume":"291","author":"Viereck","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"B46","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00223-002-0025-x","article-title":"Bisphosphonate actions on cancer","volume":"73","author":"Yoneda","year":"2003","journal-title":"Calcif Tissue Int"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1210\/jc.2009-1947","article-title":"Long-term use of bisphosphonates in osteoporosis","volume":"95","author":"Watts","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1517\/14656566.9.6.1013","article-title":"Zoledronic acid for cancer therapy \u2013 induced and postmenopausal bone loss","volume":"9","author":"Brufsky","year":"2008","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 1","key":"B49","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1053\/j.seminoncol.2010.06.004","article-title":"Bisphosphonates in lung cancer: more than a palliative therapy?","volume":"37","author":"Jahanzeb","year":"2010","journal-title":"Semin Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1093\/annonc\/mdp378","article-title":"Antitumoral effect of the bisphosphonate zoledronic acid against visceral metastases in an adrenocortical cancer patient","volume":"20","author":"Boudou-Rouquette","year":"2009","journal-title":"Ann Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/j.1442-2042.2008.02044.x","article-title":"Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: a case report","volume":"15","author":"Kijima","year":"2008","journal-title":"Int J Urol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/sj.bjc.6603548","article-title":"Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma","volume":"9","author":"Horie","year":"2007","journal-title":"Br J Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1002\/cncr.21530","article-title":"Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice","volume":"104","author":"Ory","year":"2005","journal-title":"Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.canlet.2008.09.026","article-title":"Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model","volume":"274","author":"Koto","year":"2009","journal-title":"Cancer Lett"},{"key":"B56","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.bone.2005.02.020","article-title":"Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma","volume":"37","author":"Heymann","year":"2005","journal-title":"Bone"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/jor.20129","article-title":"Anticancer effects of zoledronic acid against human osteosarcoma cells","volume":"24","author":"Kubista","year":"2006","journal-title":"J Orthop Res"},{"key":"B58","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00280-007-0580-y","article-title":"Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells","volume":"62","author":"Kubo","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.canlet.2006.10.004","article-title":"Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells","volume":"250","author":"Benassi","year":"2007","journal-title":"Cancer Lett"},{"key":"B60","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1158\/1078-0432.CCR-08-1616","article-title":"Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model","volume":"15","author":"Labrinidis","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1002\/cncr.25744","article-title":"Addition of pamidronate to chemotherapy for the treatment of osteosarcoma","volume":"117","author":"Meyers","year":"2011","journal-title":"Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1517\/13543784.17.11.1703","article-title":"Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing\u2019s sarcoma and osteosarcoma)","volume":"17","author":"Anderson","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"B63","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/00001813-200310000-00013","article-title":"The bisphosphonate pamidronate is a potent inhibitor of Ewing\u2019s sarcoma cell growth in vitro","volume":"14","author":"Sonnemann","year":"2003","journal-title":"Anticancer Drugs"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1002\/cncr.21383","article-title":"Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma","volume":"104","author":"Zhou","year":"2005","journal-title":"Cancer"},{"key":"B65","doi-asserted-by":"publisher","first-page":"7610","DOI":"10.1158\/0008-5472.CAN-09-4272","article-title":"Zoledronic acid as a new adjuvant therapeutic strategy for Ewing\u2019s sarcoma patients","volume":"70","author":"Odri","year":"2010","journal-title":"Cancer Res"},{"key":"B66","first-page":"2147","article-title":"Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines","volume":"28","author":"Murayama","year":"2008","journal-title":"Anticancer Res"},{"key":"B67","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1159\/000092489","article-title":"Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro","volume":"27","author":"Neville-Webbe","year":"2006","journal-title":"Tumour Biol"},{"key":"B68","first-page":"5380","article-title":"Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice","volume":"9","author":"Yano","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/1471-2407-14-169","article-title":"Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing\u2019s sarcoma via inhibition of cell migration","volume":"14","author":"Odri","year":"2014","journal-title":"BMC Cancer"},{"key":"B70","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.ejca.2013.03.018","article-title":"Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children\u2019s Oncology Group","volume":"49","author":"Goldsby","year":"2013","journal-title":"Eur J Cancer"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1002\/jbmr.453","article-title":"Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patient","volume":"26","author":"Battaglia","year":"2011","journal-title":"J Bone Miner Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.bone.2014.08.018","article-title":"Preclinical evidence of potential craniofacial adverse effect of zoledronic acid in pediatric patients with bone malignancies","volume":"68","author":"L\u00e9zot","year":"2014","journal-title":"Bone"},{"key":"B73","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1182\/blood.V98.13.3534","article-title":"Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma","volume":"98","author":"Croucher","year":"2001","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1172\/JCI11685","article-title":"Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone","volume":"107","author":"Zhang","year":"2001","journal-title":"J Clin Invest"},{"key":"B75","first-page":"1637","article-title":"Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma","volume":"61","author":"Michigami","year":"2001","journal-title":"Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1111\/j.1349-7006.2008.00919.x","article-title":"Conditioned media from mouse osteosarcoma cells promote MC3T3-E1 cell proliferation using JAKs and PI3-K\/Akt signal crosstalk","volume":"99","author":"Mori","year":"2008","journal-title":"Cancer Sci"},{"key":"B77","first-page":"261","article-title":"RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells","volume":"28","author":"Wittrant","year":"2006","journal-title":"Int J Oncol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1242\/jcs.094029","article-title":"Homotypic RANKL signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells","volume":"125","author":"Beristain","year":"2012","journal-title":"J Cell Sci"},{"key":"B79","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1002\/jbmr.455","article-title":"Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models","volume":"26","author":"Rousseau","year":"2011","journal-title":"J Bone Miner Res"},{"key":"B80","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1517\/14728214.2013.823948","article-title":"Drugs targeting the bone microenvironment: new therapeutic tools in Ewing\u2019s sarcoma?","volume":"18","author":"Redini","year":"2013","journal-title":"Expert Opin Emerg Drugs"},{"key":"B81","doi-asserted-by":"publisher","first-page":"7308","DOI":"10.1158\/0008-5472.CAN-06-4130","article-title":"Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption","volume":"67","author":"Lamoureux","year":"2007","journal-title":"Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1158\/1535-7163.MCT-08-0497","article-title":"Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma","volume":"7","author":"Lamoureux","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"B83","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"B84","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1359\/jbmr.2000.15.1.2","article-title":"The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption","volume":"15","author":"Hofbauer","year":"2000","journal-title":"J Bone Miner Res"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1210\/endo.139.3.5837","article-title":"Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG\/OCIF inhibits osteoclastogenesis in vitro","volume":"139","author":"Yasuda","year":"1998","journal-title":"Endocrinology"},{"key":"B86","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1016\/S0002-9440(10)63560-2","article-title":"Receptor activator of nuclear factor kappaB ligand (RANKL)\/osteoprotegerin (OPG) ratio is increased in severe osteolysis","volume":"163","author":"Grimaud","year":"2003","journal-title":"Am J Pathol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"14363","DOI":"10.1074\/jbc.273.23.14363","article-title":"Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL","volume":"273","author":"Emery","year":"1998","journal-title":"J Biol Chem"},{"key":"B88","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.bbcan.2009.08.004","article-title":"Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment","volume":"1805","author":"Lamoureux","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"B89","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1158\/1078-0432.CCR-09-1779","article-title":"Preclinical evidence that use of TRAIL in Ewing\u2019s sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival","volume":"16","author":"Picarda","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B90","first-page":"10117","article-title":"Involvement of TNF-related apoptosis-inducing ligand (TRAIL) induction in interferon gamma-mediated apoptosis in Ewing tumor cells","volume":"10","author":"Abadie","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"B91","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.bone.2010.11.003","article-title":"Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic\/blastic prostate cancer lesion","volume":"48","author":"Virk","year":"2011","journal-title":"Bone"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1359\/jbmr.060706","article-title":"Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration","volume":"21","author":"Feeley","year":"2006","journal-title":"J Bone Miner Res"},{"key":"B93","doi-asserted-by":"publisher","first-page":"539","DOI":"10.4161\/cbt.9.7.11266","article-title":"Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L\/TRAIL\/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis","volume":"9","author":"Holland","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"B94","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","article-title":"A study of the biological receptor of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer","volume":"12","author":"Body","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B96","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1470-2045(10)70010-3","article-title":"Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study","volume":"11","author":"Thomas","year":"2010","journal-title":"Lancet Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2015.05.036","article-title":"The hypoxic tumor microenvironment: a driving force for breast cancer progression","author":"Semenza","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"B101","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00066-001-0804-8","article-title":"Prognostic impact of tumor perfusion in MR-imaging studies in Ewing tumors","volume":"177","author":"Dunst","year":"2001","journal-title":"Strahlenther Onkol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1158\/1538-7445.AM10-444","article-title":"Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing\u2019s sarcoma cells in vitro","volume":"70","author":"Aryee","year":"2010","journal-title":"Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","first-page":"e5415","DOI":"10.1371\/journal.pone.0005415","article-title":"A molecular function map of Ewing\u2019s sarcoma","volume":"4","author":"Kauer","year":"2009","journal-title":"PLoS One"},{"key":"B104","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/path.2819","article-title":"Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumor progression","volume":"223","author":"Berghuis","year":"2011","journal-title":"J Pathol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10456-008-9109-1","article-title":"VEGF165 expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing\u2019s sarcoma vasculature","volume":"11","author":"Reddy","year":"2008","journal-title":"Angiogenesis"},{"key":"B106","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3727\/096504009789954627","article-title":"VEGF165 promotes the osteolytic bone destruction of Ewing\u2019s sarcoma tumors by upregulating RANKL","volume":"18","author":"Guan","year":"2009","journal-title":"Oncol Res"},{"key":"B107","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/sj.bjc.6605775","article-title":"Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing\u2019s sarcoma family of tumours by activating the FGFR-PI3K-Rac1 pathway","volume":"103","author":"Kamura","year":"2010","journal-title":"Br J Cancer"},{"key":"B108","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.bone.2014.06.023","article-title":"Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer","volume":"66","author":"Haider","year":"2014","journal-title":"Bone"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1158\/0008-5472.CAN-13-2645","article-title":"Contribution of the host microenvironment to cancer-induced bone disease","volume":"74","author":"Olechnowicz","year":"2014","journal-title":"Cancer Res"},{"key":"B110","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: a fatal attraction","volume":"11","author":"Weilbaecher","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"B111","doi-asserted-by":"publisher","first-page":"6500","DOI":"10.1073\/pnas.1221403110","article-title":"Modeling Ewing sarcoma tumors in vitro with 3D scaffolds","volume":"110","author":"Fong","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9\u201380","key":"B112","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.addr.2014.07.012","article-title":"3D tissue-engineered model of Ewing\u2019s sarcoma","volume":"7","author":"Lamhamedi-Cherradi","year":"2014","journal-title":"Adv Drug Del Rev"},{"key":"B113","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.1016\/j.biomaterials.2014.03.081","article-title":"Bioengineered human tumor within a bone niche","volume":"35","author":"Villasante","year":"2014","journal-title":"Biomaterials"},{"key":"B114","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.ejca.2008.11.045","article-title":"Preclinical evaluation of vascular disrupting agents in Ewing\u2019s sarcoma family of tumours","volume":"45","author":"Dalal","year":"2009","journal-title":"Eur J Cancer"},{"key":"B115","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1203\/00006450-200103000-00006","article-title":"Establishment of an in vivo model for pediatric Ewing tumours by transplantation into NOD\/SCID mice","volume":"49","author":"Vormoor","year":"2001","journal-title":"Pediatr Res"},{"key":"B116","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/nm886","article-title":"Rapid myeloerythroid repopulation after intrafemoral transplantation in NOD-SCID mice reveals a new class of human stem cells","volume":"9","author":"Mazurier","year":"2003","journal-title":"Nat Med"},{"issue":"1","key":"B117","doi-asserted-by":"publisher","first-page":"e85128","DOI":"10.1371\/journal.pone.0085128","article-title":"Development of a preclinical orthotopic xenograft model of Ewing sarcoma and other human malignant bone disease using advanced in vivo imaging","volume":"9","author":"Vormoor","year":"2014","journal-title":"PLoS One"}],"container-title":["Frontiers in Oncology"],"original-title":[],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T02:22:11Z","timestamp":1498270931000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/Article\/10.3389\/fonc.2015.00279\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,23]]},"references-count":117,"URL":"https:\/\/doi.org\/10.3389\/fonc.2015.00279","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,23]]}}}